ErinHaagBreeseMDPhD

PubMed

• Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukae...
  Francis R LeBlanc, Erin H Breese, Karen C Burns, Ellen K Chang, LaQuita M Jones
  British Journal of Haematology. 2024-09-01
• 3 citations
  The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy ...
  Jeremy D Rubinstein, Erin H Breese, M Christa Krupski, Maureen M O'Brien, Christopher E Dandoy
  Transplantation and Cellular Therapy. 2023-05-01
• 19 citations
  Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
  Laurence C Cheung, Carlos Aya-Bonilla, Mark N Cruickshank, Sung K Chiu, Vincent Kuek
  Leukemia. 2023-01-01

Abstracts/Posters

• V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia
  Erin H. Breese, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• In Vitro Approach for the Identification of Exceptional Responders in Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018